



## **Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference**

January 28, 2025

FREMONT, Calif.--(BUSINESS WIRE)--Jan. 28, 2025-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 11, 2025, at The Cliff Lodge in Snowbird, UT.

### **About Personalis, Inc.**

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit [www.personalis.com](http://www.personalis.com) and connect with us on [LinkedIn](#) and X ([Twitter](#)).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250128738322/en/): <https://www.businesswire.com/news/home/20250128738322/en/>

#### Investors:

Caroline Corner

[investors@personalis.com](mailto:investors@personalis.com)

415-202-5678

#### Media:

[pr@personalis.com](mailto:pr@personalis.com)

Source: Personalis, Inc.